High anti-tumor necrosis factor alpha treatment trough concentrations are not associated with higher rate of adverse events in pediatric patients with inflammatory bowel disease

被引：0
|
作者：
Zvuloni, M. [1 ]
Matar, M. [2 ]
Levi, R. [3 ]
Shamir, R. [1 ,2 ]
Assa, A. [2 ,4 ]
机构：
[1] Tel Aviv Univ, Sackler Fac Med, Dept Med, Tel Aviv, Israel
[2] Schneider Childrens Hosp, Inst Gastroenterol Nutr & Liver Dis, Petah Tiqwa, Israel
[3] Schneider Childrens Hosp, Pediat Dept A, Petah Tiqwa, Israel
[4] Ben Gurion Univ Negev, Dept Med, Beer Sheva, Israel
来源：
JOURNAL OF CROHNS & COLITIS | 2021年 / 15卷
关键词：
D O I：
10.1093/ecco-jcc/jjab076.506
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P382
引用
收藏
页码：S395 / S395
页数：1
相关论文
共 50 条
  • [21] Reversal of Immunogenicity in Pediatric Inflammatory Bowel Disease Patients Receiving Anti-Tumor Necrosis Factor Medications
    Kang, Elise
    Khalili, Ali
    Splawski, Judy
    Sferra, Thomas J.
    Moses, Jonathan
    PEDIATRIC GASTROENTEROLOGY HEPATOLOGY & NUTRITION, 2018, 21 (04) : 329 - 335
  • [22] Anti-tumor necrosis factor therapy for pediatric inflammatory bowel diseases
    Bujanover, Yoram
    Weiss, Batia
    ISRAEL MEDICAL ASSOCIATION JOURNAL, 2008, 10 (8-9): : 634 - 639
  • [23] Infections in patients with inflammatory bowel disease receiving anti-tumor necrosis factor agents are not associated with higher serum drug levels
    Chu, I. E.
    Su, H. Y.
    Martin, C.
    Sparrow, M. P.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2018, 33 : 89 - 90
  • [24] The gut fungal and bacterial microbiota in pediatric patients with inflammatory bowel disease introduced to treatment with anti-tumor necrosis factor-α
    Rebecka Ventin-Holmberg
    Miikka Höyhtyä
    Schahzad Saqib
    Katri Korpela
    Anne Nikkonen
    Anne Salonen
    Willem M. de Vos
    Kaija-Leena Kolho
    Scientific Reports, 12
  • [25] The gut fungal and bacterial microbiota in pediatric patients with inflammatory bowel disease introduced to treatment with anti-tumor necrosis factor-α
    Ventin-Holmberg, Rebecka
    Hoyhtya, Miikka
    Saqib, Schahzad
    Korpela, Katri
    Nikkonen, Anne
    Salonen, Anne
    de Vos, Willem M.
    Kolho, Kaija-Leena
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [26] Management of Inflammatory Bowel Disease with Infliximab and Other Anti-Tumor Necrosis Factor Alpha Therapies
    Fernando Magro
    Francisco Portela
    BioDrugs, 2010, 24 : 3 - 14
  • [27] Anti-Tumor Necrosis Factor Alpha Antibodies for Remission Maintenance Therapy in Inflammatory Bowel Disease
    Neubauer, Katarzyna
    Kempinski, Radoslaw
    Poniewierka, Elzbieta
    ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, 2010, 19 (02): : 143 - 149
  • [28] Management of Inflammatory Bowel Disease with Infliximab and Other Anti-Tumor Necrosis Factor Alpha Therapies
    Magro, Fernando
    Portela, Francisco
    BIODRUGS, 2010, 24 : 3 - 14
  • [29] Optimizing anti-tumor necrosis factor strategies in inflammatory bowel disease
    William J. Sandborn
    Current Gastroenterology Reports, 2003, 5 (6) : 501 - 505
  • [30] Anti-tumor Necrosis Factor Agents and Tuberculosis in Inflammatory Bowel Disease
    Yunho, Jung
    KOREAN JOURNAL OF GASTROENTEROLOGY, 2020, 75 (01): : 1 - 3
12345